NutriBand Inc.
www.nutriband.comAI Executive Summary
AI-powered analysis of 10-Q filing content
NutriBand continues to operate as a pre-revenue-stage pharmaceutical company with no FDA-approved product, and its financial position weakened over the quarter: cash fell 25% to $3.4M, revenue declined ~30% YoY, and the accumulated deficit grew to $48.8M. While net losses narrowed year-over-year due to cost cuts, stockholders' equity dropped from $6.68M to $5.33M, and disclosure controls remain ineffective due to persistent material weaknesses. The company also added new macro risk disclosures (U.S.-Iran conflict, tariffs, AI-market-driven capital market shifts) reflecting heightened uncertainty about capital access.
Red Flags Detected (6)
Disclosure controls and procedures deemed not effective due to ongoing material weaknesses (segregation of duties, qualified personnel, third-party reliance)
No FDA-approved product on the market; lead product (abuse-deterrent fentanyl transdermal system) still under development
Cash declined 25% in six months ($4.57M to $3.42M) while accumulated deficit rose to $48.8M
3 more red flags detected
Key Takeaways
Company remains in a going-concern-sensitive position with no approved marketable drug product
Net loss decreased YoY primarily due to lower R&D and SG&A spending, not improved revenue performance
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.